13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a patient with gastroesophageal junction adenocarcinoma in a Phase Ib trial to treat locally advanced or...
23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
21:03 , Dec 8, 2017 |  BC Week In Review  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
22:07 , Dec 6, 2017 |  BC Extra  |  Company News

Newco Ayala in-licenses BMS gamma secretase inhibitors

Bristol-Myers Squibb Co. (NYSE:BMY) granted newco Ayala Pharmaceuticals Inc. (Rehovot, Israel) exclusive, worldwide rights to BMS-906024 and BMS-986115. Ayala plans to develop the gamma secretase inhibitors as targeted treatments for cancers harboring specific Notch alterations....
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

BMS-906024: Interim Phase I data

Interim data from 25 patients with relapsed or refractory T cell ALL or T cell lymphoblastic lymphoma in an open-label, dose-escalation Phase I trial showed that once-weekly 0.6, 4 and 6 mg IV BMS-906024 led...